• Giuseppe Tridente


Ofatumumab (Arzerra®, GSK) is a humanized IgG1k monoclonal antibody directed to the CD20 surface antigen expressed on B lymphocytes. In 2008, EMEA designated this monoclonal as orphan drug for the treatment of B cell chronic lymphocytic leukemia (CLL). In 2009, FDA granted orphan drug designation for the same treatment, and subsequently granted accelerated approval, restricted to CLL double refractory patients to fludarabine and alemtuzumab (DR).


Rheumatoid Arthritis Patient Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Infusion Reaction Chronic Lymphocytic Leukemia Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

307171_1_En_29_MOESM1_ESM.xls (60 kb)
Supplementary material 1 (XLS 61 kb)


  1. 1.
    Ofatumumab (Arzerra ®) BLA 125326 Medical Review FDA, Sept 2009Google Scholar
  2. 2.
    Ofatumumab (Arzerra®) ODAC Briefing Document FDA, May 2009Google Scholar
  3. 3.
    Ofatumumab (Arzerra®) WC500093094 CHMP Assessment Report EMEA, Jan 2010Google Scholar
  4. 4.
    Ofatumumab (Arzerra®) Product Information GSK, Sept 2011Google Scholar
  5. 5.
    Ofatumumab (Arzerra®) WC500093091 Product Information Annex I EMEA, Aug 2012Google Scholar
  6. 6.
    Coiffier B, Lepretre S, Pedersen LM et al (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a Phase 1–2 study. Blood 111:1094–1100PubMedCrossRefGoogle Scholar
  7. 7.
    Lemery SJ, Zhang J, Rothmann MD et al (2010) U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 16:4331–4338PubMedCrossRefGoogle Scholar
  8. 8.
    Gravanis G, Ersbøll J, Skovlund E et al (2010) The European medicines agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European Medicines Agency Committee for medical products for human use. Oncologist 15:1335–1343PubMedCrossRefGoogle Scholar
  9. 9.
    Wierda WG, Kipps TJ, Mayer J et al (2010) Ofatumumab as a single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J ClinOncol 28:1749–1755CrossRefGoogle Scholar
  10. 10.
    Wierda WG, Padmanabhan S, Chan GW et al (2011) Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 118:5126–5129PubMedCrossRefGoogle Scholar
  11. 11.
    Sanford M, McCormack PL (2010) Ofatumumab. Drugs 70:1013–1019Google Scholar
  12. 12.
    Gupta IV, Jewell RC (2012) Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. Ann N Y Acad Sci 1263:43–56PubMedCrossRefGoogle Scholar
  13. 13.
    Cang S, Mukhi N, Wang K et al (2012) Novel CD20 monoclonal antibody for lymphoma therapy. J Hematol Oncol 5:64–71PubMedCrossRefGoogle Scholar
  14. 14.
    Wierda WG, Kipps TJ, Dürig J et al (2011) Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 117:6450–6458PubMedCrossRefGoogle Scholar
  15. 15.
    Baig NA, Taylor RP, Lindorfer MA et al (2012) Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement. Leuk Lymphoma 53:2218–2227PubMedCrossRefGoogle Scholar
  16. 16.
    Hegenbeek A, Gadeberg O, Johnson P et al (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 111:5486–5495CrossRefGoogle Scholar
  17. 17.
    Czuczman MS, Fayad L, Delwail V et al (2012) Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 119:3698–3704PubMedCrossRefGoogle Scholar
  18. 18.
    Czuczman MS, Hess G, Gadeberg OV et al (2012) Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. BJH 157:438–445PubMedCrossRefGoogle Scholar
  19. 19.
    Østergaard M, Baslund B, Rigby W et al (2010) Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs. Arthritis Rheum 62:2227–2238PubMedCrossRefGoogle Scholar
  20. 20.
    Taylor PC, Quattrocchi E, Mallett S et al (2011) Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomized, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 70:2119–2125PubMedCrossRefGoogle Scholar
  21. 21.
    Gensicke H, Leppert D, Yaldizli Ö et al (2012) Monoclonal antibodies and recombinant immunoglobulin’s for the treatment of multiple sclerosis. CNS Drugs 26:11–37PubMedCrossRefGoogle Scholar
  22. 22.
    Barun B, Bar-Or A (2012) Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol 142:31–37PubMedCrossRefGoogle Scholar
  23. 23.
    Bologna L, Gotti E, Manganini M et al (2012) Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 186:3762–3769CrossRefGoogle Scholar
  24. 24.
    Bauer K, Rancea M, Roloff V et al (2012) Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukemia (Review). The Cochrane Libr 11:1–108Google Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations